| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
CTMX sits in the Biotechnology industry within the Health Care sector, so this activity is best read against the sector's broader insider trend.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 1.08M | $6.93M | - | |
| VP | 300.8K | $1.93M | - | |
| CFO | 295.3K | $900.7K | - | |
| Other | 189.4K | $1.22M | - | |
| Other | 100.0K | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 4, 2019 | Rowland Lloyd A50 | General Counsel | Buy | 9,000 | $10.33 | $92,970.00 | +919.3% | |
| Dec 12, 2018 | Ray Debanjan | Chief Financial Officer | Sale+OE | 3,000 | $15.00 | $45,000.00 | -33.6% | |
| Nov 2, 2018 | McCarthy Sean A.68 | President and CEO | Sale+OE | 6,526 | $15.00 | $97,898.59 | -7.4% | |
| Nov 1, 2018 | Ray Debanjan | Chief Financial Officer | Sale+OE | 3,000 | $15.00 | $45,000.00 | -33.6% | |
| Oct 1, 2018 | Ray Debanjan | Chief Financial Officer | Sale+OE | 3,000 | $18.46 | $55,380.00 | -33.6% | |
| Sep 4, 2018 | Ray Debanjan | Chief Financial Officer | Sale+OE | 3,000 | $22.39 | $67,170.00 | -33.6% | |
| Sep 4, 2018 | McCarthy Sean A.68 | President and CEO | Sale+OE | 13,052 | $21.86 | $285,342.82 | -13.7% | |
| Aug 1, 2018 | Ray Debanjan | Chief Financial Officer | Sale+OE | 3,000 | $26.05 | $78,150.00 | -33.6% | |
| Jul 5, 2018 | McCarthy Sean A.68 | President and CEO | Sale+OE | 4,497 | $25.06 | $112,688.52 | -5.2% | |
| Jul 3, 2018 | McCarthy Sean A.68 | President and CEO | Sale+OE | 2,028 | $25.09 | $50,880.49 | -2.4% |